SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
Behavioral Evidence for Interactions between a Hallucinogenic Drug and Group II Metabotropic Glutamate Receptors
3 references·10 citing·37 second hop
Behavioral Evidence for Interactions between a Hallucinogenic Drug and Group II Metabotropic Glutamate Receptors (2000)Behavioral Evidence for Interactions betw…Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action (1998)Psilocybin induces schizophre…Radioligand binding evidence implicates the brain 5-HT2 receptor as a site of action for LSD and phenylisopropylamine hallucinogens (1988)Radioligand binding evidence …A drug discrimination analysis of lysergic acid diethylamide (LSD): in vivo agonist and antagonist effects of purported 5-hydroxytryptamine antagonists and of pirenperone, a LSD-antagonist. (1982)A drug discrimination analysi…Pharmacological Mechanism of the Non-hallucinogenic 5-HT 2A Agonist Ariadne and Analogs (2022)Pharmacological Mechanism of …Molecular Mechanisms of Psilocybin and Implications for the Treatment of Depression (2021)Molecular Mechanisms of Psilo…Psychedelics Recruit Multiple Cellular Types and Produce Complex Transcriptional Responses Within the Brain (2016)Psychedelics Recruit Multiple…Effect of Hallucinogens on Unconditioned Behavior (2016)Effect of Hallucinogens on Un…Serotonergic hallucinogens as translational models relevant to schizophrenia (2013)Serotonergic hallucinogens as…Serotonergic/glutamatergic interactions: the effects of mGlu 2/3 receptor ligands in rats trained with LSD and PCP as discriminative stimuli (2004)Serotonergic/glutamatergic in…Lysergic acid diethylamide and [−]-2,5-dimethoxy-4-methylamphetamine increase extracellular glutamate in rat prefrontal cortex (2004)Lysergic acid diethylamide an…Group II Metabotropic Glutamate Receptor Modulation of DOI-induced c-fos mRNA and Excitatory Responses in the Cerebral Cortex (2003)Group II Metabotropic Glutama…Modulation of DOI-induced increases in cortical BDNF expression by group II mGlu receptors (2002)Modulation of DOI-induced inc…Group II mGlu receptor agonists inhibit behavioural and electrophysiological effects of DOI in mice (2002)Group II mGlu receptor agonis…Evidence for 5-HT2 involvement in the mechanism of action of hallucinogenic agents (1984)PIHKAL: A Chemical Love Story (1991)d-Lysergic acid diethylamide, psilocybin, and other classic hallucinogens: Mechanism of action and potential therapeutic applications in mood disorders (2018)Effect of Psilocybin and Ketamine on Brain Neurotransmitters, Glutamate Receptors, DNA and Rat Behavior (2022)Visual Phenomenology of the LSD Flashback (1983)New World Tryptamine Hallucinogens and the Neuroscience of Ayahuasca (2016)The role of the 5-HT2A and 5-HT2C receptors in the stimulus effects of hallucinogenic drugs I: Antagonist correlation analysis (1995)Advances and Pathophysiological Models of Hallucinogenic Drug Actions in Humans: A Preamble to Schizophrenia Research (1998)Serotonin and Hallucinogens (1999)Hallucinogen-like actions of 2,5-dimethoxy-4-(n)-propylthiophenethylamine (2C-T-7) in mice and rats (2005)Psilocybin-induced stimulus control in the rat (2007)Hallucinogens as discriminative stimuli in animals: LSD, phenethylamines, and tryptamines (2008)Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer (2010)Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin (2012)Psychedelics (2016)From psychiatry to neurology: Psychedelics as prospective therapeutics for neurodegenerative disorders (2021)Neural Mechanisms and Psychology of Psychedelic Ego Dissolution (2022)Psychedelics and Neural Plasticity: Therapeutic Implications (2022)Conflict, arousal, and curiosity. (1960)Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance (2006)Dark Classics in Chemical Neuroscience: Mescaline (2018)Return of the lysergamides. Part V: Analytical and behavioural characterization of 1‐butanoyl‐d‐lysergic acid diethylamide (1B‐LSD) (2019)Serotonin 2A Receptor (5-HT 2A R) Agonists: Psychedelics and Non-Hallucinogenic Analogues as Emerging Antidepressants (2023)Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study (2016)Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial (2016)Trial of Psilocybin versus Escitalopram for Depression (2021)Therapeutic use of psilocybin: Practical considerations for dosing and administration (2022)Efficacy of psilocybin for treating symptoms of depression: systematic review and meta-analysis (2024)Hallucinogens Recruit Specific Cortical 5-HT2A Receptor-Mediated Signaling Pathways to Affect Behavior (2007)Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later (2008)Psilocybin with psychological support for treatment-resistant depression: six-month follow-up (2017)Noradrenergic and Serotonergic Function in Posttraumatic Stress Disorder (1997)Recent advances in the neuropsychopharmacology of serotonergic hallucinogens (2014)The hallucinogenic world of tryptamines: an updated review (2015)Acute effects of ayahuasca on neuropsychological performance: differences in executive function between experienced and occasional users (2013)Drug discrimination studies with MDMA and amphetamine (1988)Hallucinogenic drug interactions with neurotransmitter receptor binding sites in human cortex (1989)
this work references cited by second hop

References

  • 1998Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action1,015 cited
  • 1988Radioligand binding evidence implicates the brain 5-HT2 receptor as a site of action for LSD and phenylisopropylamine hallucinogens343 cited
  • 1982A drug discrimination analysis of lysergic acid diethylamide (LSD): in vivo agonist and antagonist effects of purported 5-hydroxytryptamine antagonists and of pirenperone, a LSD-antagonist.167 cited

Cited by

  • 2021Molecular Mechanisms of Psilocybin and Implications for the Treatment of Depression127 cited
  • 2004Lysergic acid diethylamide and [−]-2,5-dimethoxy-4-methylamphetamine increase extracellular glutamate in rat prefrontal cortex119 cited
  • 2016Effect of Hallucinogens on Unconditioned Behavior109 cited
  • 2002Group II mGlu receptor agonists inhibit behavioural and electrophysiological effects of DOI in mice97 cited
  • 2016Psychedelics Recruit Multiple Cellular Types and Produce Complex Transcriptional Responses Within the Brain86 cited
  • 2004Serotonergic/glutamatergic interactions: the effects of mGlu 2/3 receptor ligands in rats trained with LSD and PCP as discriminative stimuli79 cited
  • 2002Modulation of DOI-induced increases in cortical BDNF expression by group II mGlu receptors72 cited
  • 2003Group II Metabotropic Glutamate Receptor Modulation of DOI-induced c-fos mRNA and Excitatory Responses in the Cerebral Cortex71 cited
  • 2013Serotonergic hallucinogens as translational models relevant to schizophrenia69 cited

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work

  • 2022Pharmacological Mechanism of the Non-hallucinogenic 5-HT 2A Agonist Ariadne and Analogs68 cited